Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1477 • ACR Convergence 2024
Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study
Alice Gottlieb¹, Elena Muensterman², Alan Kivitz³, Eva Dokoupilova⁴, Apinya Lertratanakul⁵, Ting Hong⁵, Jingjing Chen⁵ and Xenofon Baraliakos⁶, ¹Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ²Takeda Development Center Americas, Cambridge, MA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Medical Plus, s.r.o., Uherske Hradiste, and Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Prague, Czech Republic, ⁵Takeda Development Center Americas, Inc., Cambridge, MA, ⁶Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany
Background/Purpose: Zasocitinib (TAK-279) is a highly selective, oral, allosteric tyrosine kinase 2 (TYK2) inhibitor. In a phase 2b trial in patients with active psoriatic arthritis…
Abstract Number: 2047 • ACR Convergence 2024
Safety in Patients with Latent Tuberculosis Who Received Concomitant Anti-Tuberculosis Medications: Analysis of 11 Studies of Guselkumab in Psoriatic Disease
Luis Puig¹, Tsen-Fang Tsai², Enrique R. Soriano³, Tina Bhutani⁴, Megan Miller⁵, Alexa P. Kollmeier⁵, Shu Li⁵, Yin You⁵, Melissa Petrick⁵, Hewei Li⁶, Hetal Patel⁷, Frederic Lavie⁸, Melinda Gooderham⁹, Angela Londoño¹⁰, Mark Lebwohl¹¹ and Peter Nash¹², ¹Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, ²National Taiwan University Hospital, Taipei, Taiwan (Republic of China), ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴University of California San Francisco Medical Center, San Francisco, CA, ⁵Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, ⁶Janssen Pharmaceutical, Hopewell Township, NJ, ⁷Pharmaceutical Companies of Johnson & Johnson, Naperville, IL, ⁸Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁹SKiN Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada, ¹⁰CES University, Medellín, Colombia, ¹¹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ¹²School of Medicine, Griffith University, Sunshine Coast, Queensland, Australia
Background/Purpose: Certain psoriatic disease treatments, including TNF-α inhibitors (TNFi), increase risk of latent tuberculosis infection (LTBI) activation.1,2 Current treatment guidelines recommend TB screening before initiating…
Abstract Number: 2322 • ACR Convergence 2024
Predictors of Work Impairment and Absence Amongst People with Psoriatic Arthritis (PsA) – Evidence from the British Society for Rheumatology PsA Register (BSR-PsA)
Lili Xu¹, Gareth Jones¹, Ovidiu Rotariu¹, Philip S. Helliwell², Stefan Siebert³, Rosemary Hollick¹ and Gary Macfarlane¹, ¹University of Aberdeen, Aberdeen, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ³School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: People with PsA often report that their condition affects their ability to work. Poor work outcomes, such as work impairment, absence or leaving work,…
Abstract Number: 2339 • ACR Convergence 2024
Increased Risk of Psoriatic Arthritis in Patients with Familial Mediterranean Fever: A Population-Based Cohort Study
Devy Zisman¹, Beatris Slutsker², Nili Stein³, Tal Gazitt⁴, Amir Haddad⁵, Ilan Feldhamer⁶, Arnon Dov Cohen⁶ and Walid Saliba³, ¹Carmel Medical Center, Haifa, Israel, ²The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, ³Department of Community Medicine and Epidemiology, Haifa, Israel, ⁴Carmel Hospital, Haifa, Israel, ⁵Carmel Medical Centre, Haifa, Israel, ⁶Chief Physician’s Office, Central Headquarters, Tel Aviv, Israel
Background/Purpose: Familial Mediterranean fever (FMF) is considered the prototype of autoinflammatory diseases, typically regarded as recessively inherited and caused by mutations in the pyrin protein…
Abstract Number: 2366 • ACR Convergence 2024
Improvement in Pain-Associated Biomarkers with Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with PsA in a Double-Blind Phase 2 Study (IM011-084)
Philip Mease¹, Christopher Ritchlin², Lu Gao³, Peter Schafer⁴, Miroslawa Nowak³, Ian M. Catlett³ and Jinqi Liu³, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ³Bristol Myers Squibb, Princeton, NJ, ⁴Bristol Myers Squibb, BELLE MEAD, NJ
Background/Purpose: Pain is a core domain of PsA, and reduction of pain is a primary treatment concern for patients with PsA. Pain has been reported…
Abstract Number: 0156 • ACR Convergence 2024
Psoriasis and Psoriatic Arthritis Are Independent Risk Factors for Non-Fatal Cardiovascular Admissions in Transition-Age Young Adults
Anurag Goel¹, Joshua Tanzer² and Vinit Gilvaz³, ¹The Warren Alpert Medical School of Brown University, Providence, RI, ²Lifespan Biostatistics, Epidemiology, Research Design, and Informatics Core, Providence, RI, ³The Warren Alpert Medical School of Brown University, East Providence, RI
Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated…
Abstract Number: 0549 • ACR Convergence 2024
Global Distribution and Determinants of Diagnostic Delay Across Diverse Spondyloarthritis Entities: Data from the International ASAS-Perspa Study
Nelly Ziade¹, Sherif Gamal², Maroun Aoun³, Ihsane Hmamouchi⁴, Clementina López Medina⁵, Maxime Dougados⁶ and Bassel Elzorkany⁷, and ASAS-PerSpA, ¹Saint-Joseph University, Beirut, Lebanon, ²Cairo University, Cairo, Egypt, ³Saint Joseph University, Beirut, Lebanon, ⁴Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco, ⁵Reina Sofia University Hospital, Cordoba, Spain, ⁶Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁷Private (BZRC), Cairo, Egypt
Background/Purpose: Diagnostic delay (DD) in spondyloarthritis (SpA) is well documented, but most of the available data are reported in patients with axial SpA (axSpA). In…
Abstract Number: 0598 • ACR Convergence 2024
Cardio-metabolic Effects of Apremilast in Patients with Psoriatic Arthritis: A Prospective Cohort Study
Eva van Geel¹, Romy Hansildaar², Fatih Çoban¹, Bas Dijkshoorn¹, Maaike Heslinga¹, Reinhard Bos³, Mies Korteweg¹, Arno Van Kuijk¹ and Michael Nurmohamed⁴, ¹Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center location Reade, Amsterdam, Netherlands, ³Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁴Reade and Amsterdam UMC, Kortenhoef, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is associated with metabolic and cardiovascular disease. Studies have suggested that treatment with apremilast is associated with weight loss and other…
Abstract Number: 1098 • ACR Convergence 2024
Prognostic Value of Hyperuricemia in Developing Cardiovascular Events in Patients with Chronic Inflammatory Arthritis: A 10-Year Prospective Study
Antonio Avilés¹, Zulema Plaza², Fernando Sánchez-Alonso³, Santos Castañeda⁴, Benjamin fernandez-Gutierrez⁵, César Díaz⁶, Pilar Font⁷, Olga Martinez⁸, Emilio Giner⁹, José Miguel Senabre¹⁰, Amalia Rueda¹¹, Ana Perez¹², Gines Sanchez¹³, Carlos Gonzalez¹⁴, Javier García¹⁵, Javier Llorca¹⁶, Miguel Angel Gonzalez-Gay¹⁷ and Mariano Andres¹⁸, and CARMA project, reserch group., ¹Rheumatology section, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain, Alicante, Spain, ²Fundacion Española de Reumatología, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, ⁶Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁸Hospital Universitario de Salamanca, Zamora, Spain, ⁹Hospital Royo Villanova, Teruel, Spain, ¹⁰Hospital Marina Baixa Alicante, Alicante, Spain, ¹¹Hospital General de Valencia, VALENCIA, Comunidad Valenciana, Spain, ¹²Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, ¹³Hospital General de Albacete, Albacete, Spain, ¹⁴Hospital Universitario Lucus Augusti; Biodiscovery HULA-USC Group, Instituto de Investigación Sanitaria de Santiago de Compostela IDIS., Lugo, Spain, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶CIBER Epidemiología y Salud Pública (CIBERESP) and Department of Medical and Surgical Sciences, University of Cantabria, Santander, Spain, ¹⁷University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ¹⁸Hospital General Universitario de Alicante, Alicante, Spain
Background/Purpose: The role of concurrent hyperuricemia as a cardiovascular risk factor in patients with chronic inflammatory arthritis (CIA) has yet to be studied. We aim…
Abstract Number: 1455 • ACR Convergence 2024
Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients with Psoriatic Arthritis
Fadi Kharouf¹, Shangyi Gao², Ali Alhadri², Daniel Pereira³, Richard Cook⁴, Vinod Chandran⁵ and Dafna Gladman⁶, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Waterloo, Waterloo, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Secondary failure to biologic therapy is challenging and contributes to the complexity of managing psoriatic arthritis (PsA). In this study, we aimed to define…
Abstract Number: 1478 • ACR Convergence 2024
Associations Between Clinical Characteristics and Screening MRI Findings: Exploratory Analysis of the Ongoing Phase 4, Multicenter, Randomized, Controlled STAR Study of Biologic-Naïve Patients with PsA with MRI-Confirmed Axial Involvement
Xenofon Baraliakos¹, Paul Bird², Atul Deodhar³, Dafna Gladman⁴, Philip S. Helliwell⁵, Denis Poddubnyy⁶, Arthur Kavanaugh⁷, Mikkel Ostergaard⁸, Enrique R. Soriano⁹, Lai-shan Tam¹⁰, Soumya Chakravarty¹¹, Evan Leibowitz¹², Cinty Gong¹³, Stephen Xu¹⁴, Thomas Fuerst¹⁵, Nadeem Saeed¹⁶, Robert Landewé¹⁷ and Philip Mease¹⁸, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²University of New South Wales, Randwick, NSW, Sydney, New South Wales, Australia, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁶Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁷University of California San Diego, La Jolla, CA, ⁸Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ⁹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁰The Chinese University of Hong Kong, New Territories, Hong Kong, ¹¹Janssen Scientific Affairs, LLC, Horsham/ Drexel University College of Medicine, Philadelphia, Horsham, PA, ¹²Janssen Scientific Affairs, LLC, Fair Lawn, NJ, ¹³Janssen Scientific Affairs, Horsham, PA, ¹⁴Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, ¹⁵Clario, San Mateo, CA, ¹⁶Clario, San Mateo, ¹⁷Amsterdam University Medical Center, Meerssen, Netherlands, ¹⁸Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Patients (pts) with PsA can develop axial inflammation in the SI joints (SIJs) and/or spine. Although validated classification criteria for axial spondyloarthritis exist, established…
Abstract Number: 2050 • ACR Convergence 2024
Clinical Enthesitis Concerns Half the Patients with Psoriatic Arthritis, Is More Frequent in Trials Than in Observational Studies and Is Assessed Heterogeneously: A Systematic Review with Meta-analysis of 84,262 Patients from 212 Studies
caroline pignon¹, Laure Gossec², Bruno Fautrel³, Clementina López Medina⁴ and Noemie bibas⁵, ¹Faculté de médecine Créteil, PARIS, France, ²Sorbonne Université, Paris, France, ³INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, ⁴Reina Sofia University Hospital, Cordoba, Spain, ⁵Sorbonne Université, paris
Background/Purpose: Enthesitis is considered a hallmark of psoriatic arthritis (PsA), however data on the frequency and consequences of enthesitis are conflicting. To analyze clinical enthesitis in…
Abstract Number: 2323 • ACR Convergence 2024
The Effect of Biologic Therapies on Serum Metabolic Biomarkers in Patients with Psoriatic Arthritis
Keith Colaco¹, laura bumbulis², Vinod Chandran¹, Richard Cook³, Dafna Gladman⁴ and Lihi Eder⁵, ¹University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³University of Waterloo, Waterloo, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada
Background/Purpose: Biologic therapies, such as tumor necrosis factor-alpha inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) may affect the cardio-metabolic profile of patients with psoriatic arthritis (PsA).…
Abstract Number: 2340 • ACR Convergence 2024
Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Diagnosis Rates, Referral Pathways, and Educational Value of Screening
Jessica A Walsh¹, Shaobo Pei², Gopi Penmetsa³, Swetha Alexander⁴, Nga Lori Ly⁵, Rosario Adriana Molano-Romero⁴, April Conlon⁶, Catherine Bakewell⁷, Soumya Reddy⁸, Jose Scher⁹ and Alexis Ogdie¹⁰, ¹Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ²University of Utah, Thousand Oaks, CA, ³University Of Utah Hospital, Salt Lake City, UT, ⁴University of Utah Health, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶University of Utah, Sandy, UT, ⁷Intermountain Healthcare, Salt Lake City, UT, ⁸NYU Grossman School of Medicine, New York, NY, ⁹New York University School of Medicine, New York, NY, ¹⁰Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Diagnostic delays are common in psoriatic arthritis (PsA). Screening surveys administered in clinic can identify psoriasis patients at elevated risk for PsA who should…
Abstract Number: 2367 • ACR Convergence 2024
Updated Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Pooled Results from Phase 2b/3 Studies
Philip Mease¹, Denis Poddubnyy², Rajan Bajracharya³, Barbara Ink³, Alexander Marten⁴, Ute Massow⁴, Vishvesh Shende³, Myriam Manente⁵, Luke Peterson⁶, Katy White³, Peter Nash⁷ and Lianne S Gensler⁸, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Charite-Universitatsmedizin Berlin, Berlin, Germany, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim am Rhein, Germany, ⁵UCB Pharma, Braine-l'Alleud, Belgium, ⁶UCB Pharma, Morrisville, NC, ⁷School of Medicine, Griffith University, Sunshine Coast, Queensland, Australia, ⁸Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A. BKZ was generally well tolerated by patients (pts)…

« Previous Page
1
…
7
8
9
10
11
…
81
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].